Search results for "Highlights"
Updated guideline on managing hyperosmolar hyperglycemic state issued by U.K. experts
The recommendations from the Joint British Diabetes Societies for Inpatient Care Group cover clinical assessment and monitoring, interventions, and assessments and prevention of harm, as well as five phases of therapy.
https://diabetes.acponline.org/archives/2022/12/09/3.htm
9 Dec 2022
ADA, KDIGO offer consensus statements on managing diabetes and chronic kidney disease
The American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO) provided specific advice on use of metformin, sodium-glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and nonsteroidal mineralocorticoid receptor antagonists in patients with diabetes and chronic kidney disease.
https://diabetes.acponline.org/archives/2022/10/14/1.htm
14 Oct 2022
Initiation of glucose-lowering therapies may be associated with reduced physical activity
An analysis of 148 participants from three randomized trials found that starting liraglutide, empagliflozin, or sitagliptin was associated with reduction in physical activity of about 1,000 steps per day or 10 minutes of moderate to vigorous physical activity per day.
https://diabetes.acponline.org/archives/2022/09/16/2.htm
16 Sep 2022
Patients diagnosed by OGTT without elevated HbA1c had similar CV, renal disease risks as those without diabetes
A prospective U.K. study found that patients with diabetes based on an oral glucose tolerance test (OGTT) often did not have a diabetic HbA1c level, and risks of cardiovascular (CV) and kidney disease in these patients were similar to those in the nondiabetic general population.
https://diabetes.acponline.org/archives/2022/09/16/3.htm
16 Sep 2022
Gestational diabetes associated with risks later in life, but lifestyle makes a difference, studies find
A review found increased risks of cardiovascular and cerebrovascular disease in women who had gestational diabetes, while another study showed that five markers of a healthy lifestyle were associated with a significant reduction in risk of developing type 2 diabetes after gestational diabetes.
https://diabetes.acponline.org/archives/2022/10/14/8.htm
14 Oct 2022
Avoiding hypoglycemia most compelling reason for deintensifying diabetes meds
Researchers presented older adults with type 2 diabetes with three scenarios in which deintensification may be indicated—poor health, limited life expectancy, and high hypoglycemia risk—and found that 8%, 4%, and 75%, respectively, viewed deintensification positively.
https://diabetes.acponline.org/archives/2022/10/14/3.htm
14 Oct 2022
Disparities by race, hospital type exist in diabetes-related lower-extremity amputations
The authors of a recent study called for public awareness, screening, and accessible and early multidisciplinary care, as well as neighborhood-level public health interventions, to reduce the disproportionate burden of lower-extremity amputation in underserved communities.
https://diabetes.acponline.org/archives/2022/07/08/2.htm
8 Jul 2022
HbA1c, CGM data significantly differed in patients with kidney disease
Patients with diabetes and chronic kidney disease often had discordance between their HbA1c levels and continuous glucose monitoring (CGM) data, with the HbA1c being significantly higher on average than the CGM-calculated glucose, a French study found.
https://diabetes.acponline.org/archives/2022/05/13/2.htm
13 May 2022
Review finds blood pressure-lowering effects weaker in patients with type 2 diabetes
Absolute risk reductions did not differ substantially between people with and without type 2 diabetes because of the higher absolute cardiovascular risk among those with the condition, according to a new meta-analysis.
https://diabetes.acponline.org/archives/2022/08/12/1.htm
12 Aug 2022
Manufacturer's trials find positive results for combo drug for type 2 diabetes
Tirzepatide, a not-yet-approved dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, was tested against placebo and semaglutide in recent studies.
https://diabetes.acponline.org/archives/2021/07/09/3.htm
9 Jul 2021